On Friday, Sonic Corporation (NASDAQ:SONC)’s shares declined -1.20% to $29.72.
Sonic Corporation (SONC) declared results for the third fiscal quarter ended May 31, 2015.
Key highlights of the company’s third quarter of fiscal year 2015 comprised of:
- Net income per diluted share was $0.38 contrast with net income per diluted share of $0.30 in the prior-year period; not taking into account tax adjustments of $1.1 million, or $0.02 per share in the third fiscal quarter of 2015, earnings per share would have been $0.36, an enhance of 20% from the prior-year same period;
- System same-store sales raised 6.1%, comprising of a 6.1% same-store sales enhance at franchise drive-ins and an enhance of 5.5% at company drive-ins; and
- Company drive-in margins improved by 100 basis points.
Sonic Corp. operates and franchises a chain of quick-service drive-in restaurants in the United States. As of March 13, 2015, the company operated 3,517 restaurants in 44 states. It also leases signs and real estate. The company was founded in 1953 and is headquartered in Oklahoma City, Oklahoma.
Tiptree Financial Inc (NASDAQ:TIPT)’s shares gained 1.66% to $7.35.
Tiptree Financial Inc (TIPT) declared that it designated Sandra Bell as Chief Financial Officer of Tiptree Financial Inc. , its partner, Tiptree Operating Company, LLC and Tiptree Financial Partners, L.P. effective July 1, 2015.
Ms. Bell brings over 30 years of business experience in the financial services and energy industries, both as a public company Chief Financial Officer and as an investment banker. Most recently, Ms. Bell served as Chief Financial Officer of Prospect Mortgage, LLC (“Prospect”), a private equity owned mortgage originator and servicer, overseeing all financial activities, counting planned planning, treasury, financial reporting, bank and rating agency relationships and investor relations. Prior to joining Prospect, from 2008 to 2011, Ms. Bell served as Chief Financial Officer of PHH Corporation (“PHH”), a publicly traded, multi-divisional financial services company engaged in the private label mortgage services and fleet administration businesses. While at PHH, her responsibilities comprised of treasury, cash administration and banking relationships, planned planning, budgeting and forecasting, investor relations, accounting and public reporting, audit and tax. Prior to PHH, Ms. Bell served as Executive Vice President and Chief Financial Officer of the Federal Home Loan Bank of Cincinnati, where Ms. Bell managed its development, profitability and risk of its core business lines. She also led the planned financial administration and reporting functions, counting SEC reporting; treasury, counting funding and capital and risk administration; credit services, counting the lending and credit risk administration functions; and administration of a whole loan mortgage portfolio. Prior to assuming her position at the Federal Home Loan Bank, Ms. Bell had been a Managing Director at Deutsche Bank Securities, where she had been employed for 13 years. Ms. Bell received a Bachelor of Arts degree in Economics from The Ohio State University and a Masters in Business Administration from Harvard Business School.
In connection with Ms. Bell’s appointment, Tiptree Asset Administration Company, LLC, a partner of Operating Company (“Employer”) and Ms. Bell reached an Executive Employment Agreement dated as of June 12, 2015 (the “Employment Agreement”). Following the Employment Agreement, Ms. Bell will receive an annual base salary of $400,000 and will be eligible to receive an annual bonus. For the fiscal years 2015, 2016 and 2017, her annual bonus will be a minimum of 100% of her base salary (pro-rated for fiscal year 2015). Thereafter, Ms. Bell is eligible to receive an annual bonus in an amount determined by the Compensation, Nominating and Governance Committee of Tiptree’s board of directors based on the achievement of specific annual corporate performance objectives. Any annual bonus for the fiscal years 2015 and 2016 will be paid 50% in cash and 50% in restricted stock units (“RSUs”). Any annual bonus for the fiscal year 2017 and thereafter may be paid in cash and RSUs, but at least 50% in cash.
Tiptree Financial Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It primarily invests in healthcare facilities counting assisted-living, independent-living, memory care, skilled nursing and other healthcare and seniors-related real estate assets. The firm was formerly known as Care Investment Trust Inc. Tiptree Financial Inc was founded in 2007 and is headquartered in New York, New York. It operates as a partner of Tricadia Capital LLC.
At the end of Friday’s trade, Juno Therapeutics Inc (NASDAQ:JUNO)‘s shares dropped -4.90% to $46.61.
Juno Therapeutics Inc (JUNO) might not be turning a profit yet, but that’s no problem for CEO Hans Bishop’s personal bottom line.
Bishop is the 11th highest-paid CEO in the country, according to Bloomberg’s Pay Index, a daily ranking of the 100 top-paid executives. His pay package was worth $88.2 million at the end of 2014, Bloomberg stated Thursday, in a combination of salary, stock options and restricted shares. That was worth $7.3 million before Juno’s initial public offering in December.
Juno isn’t the only biotech to show up near the top of the list. CEO pay at Santa Monica, Calif.-based Kite Pharma and Waltham, Mass.-based Radius Health Inc. topped $95 million and $33.5 million, respectively.
Juno and Kite develop immunotherapy treatments for cancer. That’s a field investors have been excited to jump into in recent years. Immunotherapy reprograms a patient’s T cells and then infuses them back into the body, giving the immune system a boost to battle the cancer.
This treatment has been heralded in recent years as a breakthrough alternative to harsher methods, such as chemotherapy and radiation.
In small clinical trials, one of Juno’s drug candidates has achieved a 90 percent remission rate in a type of blood cancer.
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
The Medicines Company (NASDAQ:MDCO), ended its Friday’s trading session with -3.07% loss, and closed at $29.41.
The Medicines Company (MDCO) declared the approval of KENGREAL™ (cangrelor) by the U.S. Food and Drug Administration (FDA) as an adjunctive therapy to percutaneous coronary intervention (PCI) for reducing periprocedural thrombotic events in patients who have not been treated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor (GPI).
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, in addition to acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
